The debate on MSCs is over; it's time to promote MSC therapy in practice

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Tasly-MSC

More Like This

PR Newswire associated0

Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment. (Photo: Business Wire)

STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

PR Newswire associated0

First Breakthrough Study Highlights Superiority of MatriDerm® in Wound Healing

PR Newswire associated0

German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation

PR Newswire associated0

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

PR Newswire associated0

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)